{"id":"W2596694419","doi":"10.1200/jco.2012.30.15_suppl.1036","title":"A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne; University of Toronto; Kingston General Hospital; Interior Health; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; Baker Hughes (Canada); London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Rash; Clinical endpoint; Progressive disease; Adverse effect; Interim analysis; Nausea; Gastroenterology; Phases of clinical research; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001002808,0.00107955,0.001220774,0.0003962342,0.0003107041,0.0006738385,0.0008104734,0.001407954,0.01052942],"category_scores_gemma":[0.0005494362,0.0003091522,0.0006757408,0.0003909008,0.0004803027,0.0005178502,0.0002699757,0.002160046,0.001676041],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008998601,"about_ca_system_score_gemma":0.001426311,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001913503,"about_ca_topic_score_gemma":0.006113615,"domain_scores_codex":[0.9998152,0.00008476074,0.000006408963,0.0000264669,0.00001788894,0.00004929489],"domain_scores_gemma":[0.9997087,0.00003597005,0.00004413506,0.00001887874,0.00002106457,0.0001711692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6670538,0.03639165,0.00543966,0.002258098,0.001251981,0.0006344165,0.0002765235,0.002782749,0.03448109,0.0008802282,0.04203752,0.2065124],"study_design_scores_gemma":[0.8269175,0.1493669,0.009429392,0.0001349327,0.0003501654,0.0006974311,0.00006654182,0.001538961,0.00221355,0.0003984483,0.00885372,0.00003249862],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9575725,0.008724934,0.0009940275,0.002107495,0.0004026085,0.008389375,0.006675106,0.0003728026,0.01476122],"genre_scores_gemma":[0.9580992,0.005163596,0.002294603,0.003649559,0.0003045146,0.006205951,0.0114229,0.0000824816,0.01277723],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01052942,"threshold_uncertainty_score":0.03522444,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2071610312700796,"score_gpt":0.5449791943742308,"score_spread":0.3378181631041512,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}